IMR Press / RCM / Volume 19 / Issue 3 / DOI: 10.31083/j.rcm.2018.03.908
Open Access Review
Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions
Sivakumar Sudhakaran1, 2, 3, 5Teodoro Bottiglieri2, 3, 4, 5Kristen M. Tecson2, 3, 4, 5Aaron Y. Kluger2, 3, 4, 5Peter A. McCullough1, 2, 3, 4, 5,*
Show Less
1 Department of Internal Medicine, Baylor University Medical Center Roberts Hospitals, Suite H-102 3500 Gaston Ave, Dallas, TX 75246 USA
2 Baylor Jack and Jane Hamilton Heart and Vascular Hospital 621 Hall St, Dallas, TX 75226 USA
3 Baylor Heart and Vascular Institute 621 Hall St, Dallas, TX 75226 USA
4 Baylor Kimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease Baylor Research Institute at Dallas 3812 Elm Street Dallas, Texas 75226 USA
5 Baylor Scott & White Research Institute at Dallas 3310 Live Oak, Suite 501 Dallas, TX 75204 USA
Rev. Cardiovasc. Med. 2018 , 19(3), 77–88; https://doi.org/10.31083/j.rcm.2018.03.908
Published: 30 September 2018
Abstract

The role of anti-hyperlipidemic therapy remains of key importance in the treatment of atherosclerotic disease. Moreover, given an already exaggerated predisposition for vascular disease at baseline, there is a preponderance of data that show management of hyperlipidemia is especially important in patients with chronic kidney disease. This is a concise, up-to-date review of lipid physiology, alterations in lipid concentrations with progressive renal failure, and currently available and emerging hyperlipidemic treatment options. Specifically, the roles of these therapies in patients with chronic kidney disease are reviewed.

Keywords
Hyperlipidemia
chronic kidney disease (CKD)
PCSK9
lipid physiology
hyperlipidemia in CKD
hyperlipidemia management
Share
Back to top